Abnormally-fucosylated haptoglobin: a cancer marker for tumour burden but not gross liver metastasis.

A previous study has shown that there are high levels of an abnormally-fucosylated form of haptoglobin (FHp) in the blood of cancer patients (Thompson & Turner, 1987b). In this study, we investigated the expression of this substance in serial blood specimens from women with ovarian or breast can...

Descripción completa

Detalles Bibliográficos
Autores principales: Thompson, S., Cantwell, B. M., Cornell, C., Turner, G. A.
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 1991
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1977512/
https://www.ncbi.nlm.nih.gov/pubmed/1892771
_version_ 1782135277745078272
author Thompson, S.
Cantwell, B. M.
Cornell, C.
Turner, G. A.
author_facet Thompson, S.
Cantwell, B. M.
Cornell, C.
Turner, G. A.
author_sort Thompson, S.
collection PubMed
description A previous study has shown that there are high levels of an abnormally-fucosylated form of haptoglobin (FHp) in the blood of cancer patients (Thompson & Turner, 1987b). In this study, we investigated the expression of this substance in serial blood specimens from women with ovarian or breast cancer who were undergoing cytotoxic chemotherapy. The level of FHp was related to patient response to therapy status, this latter index being an indirect determination of tumour burden. FHp levels did not correlate with gross liver metastasis (as shown by CT scans or the blood levels of liver enzymes). This conclusion was further supported by results from patients with hepatocellular cancer. FHp was elevated in most of these patients, but the pattern of change did not correlate with variations in the level of the hepatoma marker, alpha-foetoprotein. It seems likely that FHp is produced by the liver. Primary and secondary tumours could release substances, such as cytokines, which interfere with fucose metabolism in the liver. IMAGES:
format Text
id pubmed-1977512
institution National Center for Biotechnology Information
language English
publishDate 1991
publisher Nature Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-19775122009-09-10 Abnormally-fucosylated haptoglobin: a cancer marker for tumour burden but not gross liver metastasis. Thompson, S. Cantwell, B. M. Cornell, C. Turner, G. A. Br J Cancer Research Article A previous study has shown that there are high levels of an abnormally-fucosylated form of haptoglobin (FHp) in the blood of cancer patients (Thompson & Turner, 1987b). In this study, we investigated the expression of this substance in serial blood specimens from women with ovarian or breast cancer who were undergoing cytotoxic chemotherapy. The level of FHp was related to patient response to therapy status, this latter index being an indirect determination of tumour burden. FHp levels did not correlate with gross liver metastasis (as shown by CT scans or the blood levels of liver enzymes). This conclusion was further supported by results from patients with hepatocellular cancer. FHp was elevated in most of these patients, but the pattern of change did not correlate with variations in the level of the hepatoma marker, alpha-foetoprotein. It seems likely that FHp is produced by the liver. Primary and secondary tumours could release substances, such as cytokines, which interfere with fucose metabolism in the liver. IMAGES: Nature Publishing Group 1991-08 /pmc/articles/PMC1977512/ /pubmed/1892771 Text en https://creativecommons.org/licenses/by/4.0/This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit https://creativecommons.org/licenses/by/4.0/.
spellingShingle Research Article
Thompson, S.
Cantwell, B. M.
Cornell, C.
Turner, G. A.
Abnormally-fucosylated haptoglobin: a cancer marker for tumour burden but not gross liver metastasis.
title Abnormally-fucosylated haptoglobin: a cancer marker for tumour burden but not gross liver metastasis.
title_full Abnormally-fucosylated haptoglobin: a cancer marker for tumour burden but not gross liver metastasis.
title_fullStr Abnormally-fucosylated haptoglobin: a cancer marker for tumour burden but not gross liver metastasis.
title_full_unstemmed Abnormally-fucosylated haptoglobin: a cancer marker for tumour burden but not gross liver metastasis.
title_short Abnormally-fucosylated haptoglobin: a cancer marker for tumour burden but not gross liver metastasis.
title_sort abnormally-fucosylated haptoglobin: a cancer marker for tumour burden but not gross liver metastasis.
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1977512/
https://www.ncbi.nlm.nih.gov/pubmed/1892771
work_keys_str_mv AT thompsons abnormallyfucosylatedhaptoglobinacancermarkerfortumourburdenbutnotgrosslivermetastasis
AT cantwellbm abnormallyfucosylatedhaptoglobinacancermarkerfortumourburdenbutnotgrosslivermetastasis
AT cornellc abnormallyfucosylatedhaptoglobinacancermarkerfortumourburdenbutnotgrosslivermetastasis
AT turnerga abnormallyfucosylatedhaptoglobinacancermarkerfortumourburdenbutnotgrosslivermetastasis

Ejemplares similares